MetLife Investment Management’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.54M | Hold |
53,414
| – | – | 0.01% | 1122 |
|
|
2025
Q1 | $1.79M | Buy |
53,414
+394
| +0.7% | +$13.2K | 0.01% | 1092 |
|
|
2024
Q4 | $2.71M | Buy |
53,020
+8,085
| +18% | +$413K | 0.01% | 888 |
|
|
2024
Q3 | $2.3M | Hold |
44,935
| – | – | 0.01% | 946 |
|
|
2024
Q2 | $2.01M | Buy |
44,935
+10,916
| +32% | +$489K | 0.01% | 968 |
|
|
2024
Q1 | $1.59M | Hold |
34,019
| – | – | 0.01% | 1058 |
|
|
2023
Q4 | $1.21M | Hold |
34,019
| – | – | 0.01% | 1200 |
|
|
2023
Q3 | $1.01M | Buy |
34,019
+5,972
| +21% | +$178K | 0.01% | 1222 |
|
|
2023
Q2 | $505K | Hold |
28,047
| – | – | ﹤0.01% | 1685 |
|
|
2023
Q1 | $450K | Hold |
28,047
| – | – | ﹤0.01% | 1703 |
|
|
2022
Q4 | $513K | Buy |
28,047
+792
| +3% | +$14.5K | ﹤0.01% | 1628 |
|
|
2022
Q3 | $535K | Buy |
27,255
+1,838
| +7% | +$36.1K | ﹤0.01% | 1591 |
|
|
2022
Q2 | $474K | Hold |
25,417
| – | – | ﹤0.01% | 1703 |
|
|
2022
Q1 | $558K | Buy |
25,417
+9,063
| +55% | +$199K | ﹤0.01% | 1705 |
|
|
2021
Q4 | $465K | Buy |
16,354
+4,706
| +40% | +$134K | ﹤0.01% | 1547 |
|
|
2021
Q3 | $245K | Hold |
11,648
| – | – | ﹤0.01% | 1961 |
|
|
2021
Q2 | $220K | Hold |
11,648
| – | – | ﹤0.01% | 2105 |
|
|
2021
Q1 | $178K | Sell |
11,648
-1,084
| -9% | -$16.6K | ﹤0.01% | 2117 |
|
|
2020
Q4 | $180K | Hold |
12,732
| – | – | ﹤0.01% | 2035 |
|
|
2020
Q3 | $200K | Hold |
12,732
| – | – | ﹤0.01% | 1866 |
|
|
2020
Q2 | $223K | Buy |
12,732
+6,897
| +118% | +$121K | ﹤0.01% | 1845 |
|
|
2020
Q1 | $85.8K | Hold |
5,835
| – | – | ﹤0.01% | 2160 |
|
|
2019
Q4 | $146K | Buy |
+5,835
| New | +$146K | ﹤0.01% | 2146 |
|
|
2019
Q3 | – | Sell |
-5,862
| Closed | -$147K | – | 2340 |
|
|
2019
Q2 | $147K | Buy |
+5,862
| New | +$147K | ﹤0.01% | 2203 |
|